Emergent Biosolutions
EBS
EBS
160 hedge funds and large institutions have $655M invested in Emergent Biosolutions in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
9% less capital invested
Capital invested by funds: $717M → $655M (-$62.7M)
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
84% less call options, than puts
Call options by funds: $7K | Put options by funds: $45K
Holders
160
Holding in Top 10
1
Calls
$7K
Puts
$45K
Top Buyers
| 1 | +$9.41M | |
| 2 | +$7.89M | |
| 3 | +$6.18M | |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$5.27M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$4.94M |
Top Sellers
| 1 | -$6.1M | |
| 2 | -$5.54M | |
| 3 | -$4.89M | |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$4.63M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
-$4.55M |